IIM
GALT icon

INTECH Investment Management’s Galectin Therapeutics GALT Stock Holding History

INTECH Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,156
Closed -$17.3K – 2542
2025
Q1 		$17.3K Buy
+14,156
New +$19.9K ﹤0.01% 2507

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

INTECH Investment Management's GALT Position: Q2 2025 in Review

INTECH Investment Management sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 14,156 shares — an estimated $17.3K sold.

INTECH Investment Management first reported a position in GALT in Q1 2025 and held it in 1 quarter. The position peaked at $17.3K in Q1 2025. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

  • INTECH Investment Management reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 14,156 Galectin Therapeutics shares in Q2 2025, an estimated $17.3K.
  • INTECH Investment Management first reported a position in Galectin Therapeutics in Q1 2025 and held it in 1 quarter.
  • INTECH Investment Management's Galectin Therapeutics position peaked at $17.3K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.